Date: 2011-04-06
Type of information: Licensing agreement
Compound: POTELLIGENT® Technology platform
Company: Oxford BioTherapeutics (UK) BioWa (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyl transferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo.
Disease:
Details: BioWa and Oxford BioTherapeutics have entered into a license agreement to provide OBT with access to BioWa’s patented POTELLIGENT® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. OBT intends to use POTELLIGENT® Technology to develop, manufacture and commercialize selected ADCC programs from its pipeline of preclinical antibodies for oncology which it has built based upon novel targets identified using its OGAP® proteomic database.
Financial terms: In return for the license, OBT will pay to BioWa undisclosed license fees, development and commercialization milestones and royalties on sales of any products that it commercializes.
Latest news:
